Rustin D. Crutchley
Clinical Associate Professor, Pharmacotherapy 509-249-7930 Cadwell 109 Yakima

Education

Bachelor of Science in biology, Duke University
Doctor of Pharmacy, University of North Carolina at Chapel Hill

Fellowships & Additional Training

PGY1-Pharmacy Practice Residency: University of Texas Health Science Center in Tyler, Texas

PGY2-HIV Specialty Residency: State University of New York at Buffalo in Buffalo, New York

STAR Health Disparities Fellowship: University of North Texas Health Science Center in Fort Worth, Texas

Licensures & Certifications

  • American Academy of HIV Medicine Pharmacist (AAHIVP)
  • Pharmacogenomics and Personalized Medicine Certificate, University of Florida
  • APhA Pharmacist & Patient-Centered Diabetes Care Certificate Training Program
  • HIV Pharmacotherapy Certificate Program, State University of New York at Buffalo
  • Teaching and Learning Certificate, State University of New York at Buffalo

Teaching

Crutchley is currently a clinical associate professor at the WSU College of Pharmacy Pharm.D. program extension located on the PNWU campus in Yakima.

Research

His research interests include complimentary alternative medicine approaches, antiretroviral treatment simplification strategies, and precision medicine in HIV patient populations.

Additional Information

Crutchley is a reviewer for the following journals: Journal of Health, Population and Nutrition, Journal of Pharmacy Practice, AIDS Research and Human Retroviruses, Lancet, The American Journal of Managed Care (AJMC), Clinical Pharmacokinetics, European Journal of Hospital Pharmacy, Pharmacotherapy, and Reviews on Recent Clinical Trials.

He is also a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Society of Infectious Diseases Pharmacists (SIDP).

Selected Peer-reviewed Publications

Hwang GS, Bhat R, Crutchley RD, Trivedi MV. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. Pharmacogenomics J. 2017. [Epub ahead of print] Aug 1. doi: 10.1038/tpj.2017.362017

Amy M. Cheng, Rustin D. Crutchley, Meghann L. Davis, Carl Mayberry, and Joseph C. Gathe Jr. Viral Suppression in the Setting of Multidrug Resistance to Nelfinavir, Tenofovir, and Abacavir: A Case Report. Journal of AIDS & Clinical Research. 2017; 8(4): DOI: 10.4172/2155-6113.1000683

Kuten SA, Patel, SJ, Baru A, Gaber AO, Crutchley RD, Ramanathan V, Knight RJ. Belatacept conversion in an HIV-positive kidney transplant recipient following anti-thymocyte golubin induction. Transpl Infect Dis 2017. [Epub ahead of print] doi:10.1111/tid.12748

Crutchley RD, Guduru RC, and Cheng AM. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV/AIDS-Research and Palliative Care. 2016; 8:47-65.

Patrick G. Clay and Rustin D. Crutchley. Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. Infectious Diseases and Therapy. 2014; 3:103-122.

Patel TS, Crutchley RD, Tucker AM, Cottreau J, Garey KW. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV/AIDS-Research and Palliative Care. 2013; 15(5):153-62.

Crutchley RD, Gathe J, Mayberry C, Trieu A, Abughosh S, Garey KW. Risk Factors for Vitamin D Deficiency in HIV-Infected Patients in the South Central United States. AIDS Res Hum Retroviruses 2012; 28(5):454-9.

RD Crutchley, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother 2010; 44(5):878-84.

Rustin D. Crutchley, Qing Ma, Adel Sulaiman, Jill Hochreitter, and Gene D. Morse. Within patient atazanavir trough concentration monitoring in HIV-1 infected patients. Journal of Pharmacy Practice 2010; 24(2):216-22.

Rezk NL, Crutchley RD, Yeh RF, Kashuba AD. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit. 2006; 28(4): 517-25.

Selected Book Chapters

Crutchley RD, Cheng AM. Human immunodeficiency virus. In: Benavides S, Nahata MC. Pediatric Pharmacotherapy 2nd edition. Lenexa, KS: American College of Clinical Pharmacy. 2017 (under review).

Crutchley RD, Felton CM. Human immunodeficiency virus. In: Benavides S, Nahata MC. Pediatric Pharmacotherapy. Lenexa, KS: American College of Clinical Pharmacy, 2013:634-69.

Rustin D. Crutchley, Amy Brilliant, Patty Fan-Havard, and Eugene Morse. Maraviroc, Antiretroviral Agents, Antiretroviral Therapy. www.antimicrobe.org. HIV Clinical Manual. 2009.

Selected Abstracts

Alexa Vyain, Rustin Crutchley, Anne Le, Joseph Gathe Jr., Carl Mayberry. Assessing treatment outcomes when switching HIV-1 infected patients from various antiretroviral therapy (ART) regimens to darunavir/cobicistat monotherapy. 31st ALCALDE/TSHP. Galveston, TX, 2017

Diane Nguyen, Alexa Vyain, Russ Crutchley, Amy Cheng, Michael Mizwa. Learning across borders: Developing a pharmacist-driven continuing professional development program through the BIPAI-PN. 8th Annual Consortium of Universities for Global Health (CUGH). Washington DC, April 2017

Christina Nance, Rosa Yeh, Roberto Arduino, Thomas Giordano, Mary Paul, Filiz O. Seeborg, Rustin Crutchley, Melinda Mata, Evelyn Leechawengwongs, and William T. Shearer. Translational Medicine in HIV-1 Infection: Preclinical and Clinical Development of the Green Tea Catechin, Epigallocatechin Gallate, as Therapy and Immunological Signatures. 20th Academy of Allergy, Asthma and Immunology (AAAAI). Atlanta, GA, March 2017

Alexa Vyain, Rustin Crutchley, Anne Le, Joseph Gathe, Jr., and Carl Mayberry. Assessing treatment outcomes when switching HIV-1 infected patients from different antiretroviral therapy (ART) regimens to darunavir/cobicistat monotherapy. 51st ASHP. Las Vegas, NV, 2016

Austin Hinkel, Shutian Kathy Ju, Rustin D Crutchley, Alexa Vyain, and Joseph Gathe, Jr. Evaluating prevalence and types of clinical pharmacy interventions in an HIV ambulatory care setting. 51st ASHP. Las Vegas, NV, 2016

Christina Nance, Rosa Yeh, Roberto Arduino, Thomas Giordano, Mary Paul, Filiz Seeborg, Tao Niu, Ming Hu, Rustin Crutchley, and William T. Shearer. Phase I Clinical Trial Results of Epigallocatechin Gallate in HIV-1-Infected Subjects. 16th Federation of Clinical Immunology Societies (FOCIS). Boston, MA, 2016

Amy M Cheng, Rustin D Crutchley, Joseph C. Gathe Jr, and Carl Mayberry. Identifying patient and antiretroviral specific factors for switching to simplified HIV treatment regimens. 30th ALCALDE/TSHP. Frisco, TX, 2016

Selected Presentations

Precision Medicine in the HIV Aging Population, World Conference on STDs, STIs & HIV/AIDS, Vancouver, Canada, July, 2017

Coordinated Management and Care Retention Strategies to Transform Patient Outcomes in HIV (ACPE 1.5HR), HIV AMCP/CMSA Chapter Meeting in San Antonio, TX, October, 2016

Polypharmacy in an Era of Antiretroviral Therapy Simplification (ACPE 1.0HR), 1st Aging with HIV Symposium in Houston, TX, September, 2016

Highlighting Pharmacogenetic Approaches for Optimizing Treatment of HIV, 4th Houston Global Health Collaborative’s Empower 2016 Conference, Rice University, Houston, TX, February, 2016

updated 08/28/2017